Can-Fite BioPharma Ltd.
CANFAMEXHealthcare● Active
$3.08
$-0.01(-0.32%)
Market Cap$1657040
P/E Ratio—
52W High$23.4
52W Low$2.83
Can-Fite BioPharma Ltd. (CANF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CANF · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 26, 2026EPS Actual
-$5.97
Est. -$27.00 · +77.9%
Revenue
$0.00B
Est. $0.00B · -32.3%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 26, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
CANF reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 27, 2026 | -$0.51 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | Apr 13, 2026 | -$27.00 | — | — | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$27.00 | -$5.97 | +77.9% | $0.00B | $0.00B | -32.3% |
| — Q3 FY2025 | Aug 28, 2025 | — | -$0.21 | — | $0.00B | — | — |
| ▲ Q2 FY2025 | Apr 14, 2025 | -$0.24 | -$0.21 | +10.7% | $0.00B | — | — |
| ▼ Q4 FY2024 | Dec 26, 2024 | -$0.27 | -$0.43 | -59.3% | $0.00B | $0.00B | +19.3% |
| ▼ Q3 FY2024 | Sep 26, 2024 | -$0.36 | -$0.40 | -11.1% | $0.00B | $0.00B | +58.0% |
| ▼ Q2 FY2024 | Jun 27, 2024 | -$0.40 | -$0.65 | -62.5% | $0.00B | $0.00B | +5.3% |
Q3 FY2026
Aug 27, 2026
EPS Actual
—
EPS Est.
-$0.51
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 13, 2026
EPS Actual
—
EPS Est.
-$27.00
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$5.97
EPS Est.
-$27.00
EPS Surpr.
+77.9%
Revenue
$0.00B
Q3 FY2025
Aug 28, 2025
EPS Actual
-$0.21
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Apr 14, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.24
EPS Surpr.
+10.7%
Revenue
$0.00B
Q4 FY2024
Dec 26, 2024Miss
EPS Actual
-$0.43
EPS Est.
-$0.27
EPS Surpr.
-59.3%
Revenue
$0.00B
Q3 FY2024
Sep 26, 2024Miss
EPS Actual
-$0.40
EPS Est.
-$0.36
EPS Surpr.
-11.1%
Revenue
$0.00B
Q2 FY2024
Jun 27, 2024Miss
EPS Actual
-$0.65
EPS Est.
-$0.40
EPS Surpr.
-62.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2030 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q2 FY2030 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q1 FY2030 | $-0.15 | $-0.15 | $-0.15 | 1 |
| Q4 FY2029 | $-0.53 | $-0.53 | $-0.53 | 1 |
| Q3 FY2029 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q2 FY2029 | $-0.01 | $-0.01 | $-0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 26, 2026 | +77.9% | $3.23 | $3.29 | +1.86% |
| — Q3 FY2025 | Aug 28, 2025 | — | $13.20 | $13.20 | +0.00% |
| ▲ Q2 FY2025 | Apr 14, 2025 | +10.7% | $31.40 | $26.00 | -17.20% |
| ▼ Q4 FY2024 | Dec 26, 2024 | -59.3% | $28.60 | $30.40 | +6.29% |
| ▼ Q3 FY2024 | Sep 26, 2024 | -11.1% | $40.60 | $41.00 | +0.99% |
| ▼ Q2 FY2024 | Jun 27, 2024 | -62.5% | $53.00 | $51.20 | -3.40% |
| ▼ Q1 FY2024 | Mar 28, 2024 | -14.8% | $45.20 | $44.40 | -1.77% |
| ▲ Q4 FY2023 | Nov 30, 2023 | +0.0% | $46.40 | $47.00 | +1.29% |
Q1 FY2026+1.86%
Report Date
Mar 26, 2026
EPS Beat/Miss
+77.9%
Price Before
$3.23
Price After
$3.29
Q3 FY2025+0.00%
Report Date
Aug 28, 2025
EPS Beat/Miss
—
Price Before
$13.20
Price After
$13.20
Q2 FY2025-17.20%
Report Date
Apr 14, 2025
EPS Beat/Miss
+10.7%
Price Before
$31.40
Price After
$26.00
Q4 FY2024+6.29%
Report Date
Dec 26, 2024
EPS Beat/Miss
-59.3%
Price Before
$28.60
Price After
$30.40
Q3 FY2024+0.99%
Report Date
Sep 26, 2024
EPS Beat/Miss
-11.1%
Price Before
$40.60
Price After
$41.00
Q2 FY2024-3.40%
Report Date
Jun 27, 2024
EPS Beat/Miss
-62.5%
Price Before
$53.00
Price After
$51.20
Q1 FY2024-1.77%
Report Date
Mar 28, 2024
EPS Beat/Miss
-14.8%
Price Before
$45.20
Price After
$44.40
Q4 FY2023+1.29%
Report Date
Nov 30, 2023
EPS Beat/Miss
+0.0%
Price Before
$46.40
Price After
$47.00
Avg Beat Reaction-4.68%
Avg Miss Reaction+0.53%
Beat Rate3 / 8 quarters
Largest Move-17.20% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CANF ends December
Can-Fite BioPharma Ltd. (CANF) most recently reported earnings on March 26, 2026 for Q1 FY2026, posting EPS of $-5.97 — beating the analyst consensus of $-27.00 by +77.9%. CANF has beaten EPS estimates for 2 consecutive quarters. The next CANF earnings date is expected around September 1, 2026.
Each quarter, investors track CANF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CANF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CANF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CANF earnings · 5 questionsCan-Fite BioPharma Ltd.'s next earnings report is expected around September 1, 2026. CANF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CANF historically reports after market close (AMC).
CANF earnings datewhen is CANF earningsCANF next earnings datewhen does CANF report earningsCANF earnings calendar
▸ Source: FMP · Can-Fite BioPharma Ltd. SEC filings · US GAAP · Can-Fite BioPharma Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026